Prix Innovation Pharmaceuticals Inc (IPIX)

Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in the development of therapies with anti-infective, oncology, anti-inflammatory, and dermatology applications. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in the business of developing or licensing small molecule therapies. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company’s efforts are primarily focused on business development for the advancement of Brilacidin. The company is primarily focused on advancement of its drug candidate Brilacidin for decreasing the incidence of severe oral mucositis as a complication of chemoradiation in oral mucositis. The firm also owns an interest in BT BeaMedical Technologies Ltd. (BTL), a private company developing an image guided surgical laser platform. The firm is monitoring BTL’s progress in advancing its laser-based thermal ablation technology platform targeting epilepsy and oncology procedures.